For media inquiries, please contact:
Stephanie Dunn, Manager, Research Communications | 604-875-2401

Click on a tag to sort the news stories by theme:

New study to determine best schedule for vaccinating boys against HPV

February 12, 2014
Share this:

Researchers at CFRI, led by Dr. Simon Dobson of CFRI’s Vaccine Evaluation Centre, have begun clinical trials on a new vaccine that protects boys against human papillomavirus (HPV). The study aims to discover how many doses of the vaccine are needed to provide optimal protection for boys through the years when they are most likely to contract HPV, their late teens and twenties. 

HPV is a sexually transmitted virus that affects men and women. Seventy-five per cent of sexually active people will have at least one HPV infection in their lifetime. Most HPV infections will clear up on their own but in some cases, cells infected with HPV can become cancerous. 

HPV is often considered to be a women’s health issue because HPV infections cause nearly all cases of cervical cancer, the second most commonly diagnosed cancer in women worldwide. In fact, HPV also causes cancers of the head, neck, anus and penis. 

In B.C., the first dose of the HPV vaccine is given to girls in Grade 6. Immunization programs in Alberta and Prince Edward Island have recently begun giving the HPV vaccine to both boys and girls. This new study will test the effectiveness of the vaccine when given to boys aged 9 to 14 years old.

“HPV affects everyone,” says Dr. Dobson. “Our goal is to prevent transmission of HPV infections by making the HPV vaccine a non-gender specific vaccine that is given to boys and girls as part of their regular public health vaccination schedules.”

A recent CFRI-led study with over 800 Canadian girls found that two doses of a four-strain HPV vaccine was associated with an immune response similar to that with three doses. This new study will evaluate will be similar in that the goal is to determine the best dosing schedule for a next-generation vaccine for boys that will protect against nine strains of the virus.

Families of boys who receive the nine-strain HPV vaccine as part of this new study will receive the vaccine free of charge; the four-strain vaccine that is currently available costs families $350.

For more information, or to participate in the study, visit the Vaccine Evaluation Centre website.

Vaccine Evaluation Centre

Since the Vaccine Evaluation Centre was founded as the first of its kind in Canada in 1988, the centre’s investigators have completed over 225 research studies with findings that have contributed towards developing new vaccines, improving vaccine safety, and refining public immunization programs.